Exchange: OTC·Updated 03:55 PM EDT
PETV logo

PETV PetVivo Holdings Inc

$0.681
$0.001
(0.15%)
Today
EarningsNov 12
Mkt Cap$25.85M
Vol3,789.00

About PETV

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. Its lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.
45

Neutral Sentiment

How do you feel about PETV?

Elephanthunter7
$PETV Materials and Methods Eighteen rhesus macaques with radiographically conrmed multi-joint OA were selected. Prior to and after injections, mobility was assessed using walking speed, accelerometry, blinded subjective clinical scoring, reach testing, and goniometry. Data was assessed using equivalence testing, as well as mixed-effects model statistics. Preliminary analyses demonstrated signicant improvements in walking speed following treatment. Walking speed increased in 91.6% of treated animals, with a mean improvement of 0.22 ± 0.11 m/s (median 0.21 m/s; range 0.03–0.41 m/s). Mixed-effects modeling demonstrated a signicant effect of timepoint on walking speed (F₃,₃₃ = 18.24, p < 0.000001). Compared with baseline, walking speed was signicantly increased at week 1 (p = 0.0002), week 2 (p < 0.0001), and week 3 (p < 0.0001).
1
HurricaneCapital
$PETV PetVivo's primate study evaluating Spryng® with OsteoCushion® Technology in rhesus macaques demonstrated a statistically significant mean walking speed improvement of 0.22 ± 0.11 meters per second within three weeks of treatment. This rapid, non-invasive mobility gain stands in stark contrast to the human knee replacement market, where standard total knee arthroplasty requires extensive structural trauma and lengthy rehabilitation—yet only 50% of patients achieve optimal mobility scores in complex tasks like descending stairs after six months. Because non-human primates share virtually identical joint biomechanics and disease progression with humans, PetVivo's ability to achieve these physical improvements while seamlessly integrating into synovial tissues with minimal local inflammation strongly validates its human market potential. This data positions the injectable hydrogel as a highly viable, pre-surgical therapeutic alternative.
NewsAndFilings
Yesterdays Recap: $PETV ANNOUNCES RELEASE OF TWO RESEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES $AMLM Announces Appointment of Independent Directors and Launch of Shareholder Ambassador Program
investical
$PETV 2 abstracts about using spryng on monkeys, while vets don’t want it. I’m waiting on abstracts about hamsters personally!

Advertisement|Remove ads.